证券代码：837023 证券简称：芭薇股份 公告编号：2025-038 广东芭薇生物科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、减持主体减持前基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 广州云美产业投资合 | 持 股 | 5% 以 | 7,142,857 | 8.33% | 北京证券交易所上市 | | 伙企业（有限合伙） | 上股东 | | | | 前取得 | 二、减持计划的实施结果 三、备查文件目录 | | | | | | 减持价格区 | | 减 | 当前持股 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 间 | | 持 | 数量（股） | | | | | 已减 | 减 | | | | 计 | | ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a revenue of 695 million yuan in 2024, representing a year-on-year growth of 48.3%, and a net profit of 45 million yuan, up 10.3% year-on-year, which met expectations [7] - The company plans to distribute a cash dividend of 3.0 yuan per share (including tax) for 2024, with a distribution ratio of 56.71% [7] - In Q1 2025, the company reported a revenue of 162 million yuan, a year-on-year increase of 40.1%, and a net profit of 9 million yuan, up 8.8% year-on-year, slightly below expectations [7] - The company is focusing on a major client strategy and has formed partnerships with emerging brands to drive revenue growth, with domestic revenue reaching 642 million yuan in 2024, a 40.5% increase [7] - The company is enhancing its raw material research and investment to improve integrated capabilities and increase the value-added of its OEM services [7] - The profit forecast for 2025-2027 has been adjusted downwards, with expected net profits of 69 million yuan, 91 million yuan, and 115 million yuan respectively [7] Financial Data and Profit Forecast - Total revenue is projected to reach 1,009 million yuan in 2025, with a year-on-year growth rate of 45.2% [6] - The gross profit margin is expected to be 26.4% in 2025, with a net profit margin of 6.5% [6] - The company’s return on equity (ROE) is forecasted to be 15.6% in 2025 [6] - The earnings per share (EPS) is projected to be 0.81 yuan in 2025 [6]

Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.5300 | 0.5400 | -1.85 | 0.5000 | | 每股净资产（元） | 4.66 | 4.27 | 9.13 | 4.09 | | 每股公积金(元) | 2.32 | 2.13 | 8.92 | 2.09 | | 每股未分配利润(元) | 1.22 | 1.06 | 15.09 | 0.96 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 6.95 | 4.69 | 48.19 | 4.59 | | 净利润(亿元) | 0.45 | 0.41 | 9.76 | 0.38 | | 净资产收益率(%) | 12.15 | 12.85 | -5.45 | 12.59 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | -- ...

广东芭薇生物科技股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 广东芭薇生物科技股份有限公司（以下简称"公司"）接到持股 5%以上股东 广州云美产业投资合伙企业（有限合伙）通知，该股东于 2025 年 3 月 5 日至 4 月 17 日期间通过集中竞价交易方式合计减持公司无限售条件流通股 993,741 股，占公 司总股本的 1.16%。 本次权益变动前，广州云美产业投资合伙企业（有限合伙）持有公司 6,708,338 股，占公司总股本的比例为 7.82%；本次权益变动后，广州云美产业投资合伙企业 （有限合伙）持有公司 5,714,597 股，占公司总股本的比例由 7.82%减少至 6.66%， 权益变动触及 1%整数倍的情形。现将具体情况公告如下： 一、本次权益变动的基本情况 （一）信息披露义务人基本情况 | 1.基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | 名称 | 持股变动时 ...

芭薇股份（837023）今日上涨8.59%，全天换手率44.51%，成交额3.53亿元，振幅17.15%。龙虎榜数据 显示，营业部席位合计净买入181.57万元。 北交所公开信息显示，当日该股因日换手率达44.51%上榜，营业部席位合计净买入181.57万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交6495.41万元，其中，买入成交额为 3338.49万元，卖出成交额为3156.92万元，合计净买入181.57万元。 具体来看，今日上榜营业部中，第一大买入营业部为东方财富证券股份有限公司拉萨团结路第一证券营 业部，买入金额为692.50万元，第一大卖出营业部为中信证券华南股份有限公司广州中山八路证券营业 部，卖出金额为721.87万元。 近半年该股累计上榜龙虎榜6次，上榜次日股价平均跌4.64%，上榜后5日平均跌14.33%。（数据宝） 芭薇股份4月15日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 东方财富证券股份有限公司拉萨团结路第一证券营业 | 692.50 | 274. ...

"聪明钱"流向曝光！暗盘资金破解主力操盘密码>> 化妆品板块走高，芭薇股份涨超10%，敷尔佳（301371）、水羊股份（300740）、拉芳家化 （603630）、贝泰妮（300957）、上海家化（600315）等跟涨。 ...

证券代码：837023 证券简称：芭薇股份 公告编号：2025-010 广东芭薇生物科技股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 广东芭薇生物科技股份有限公司（以下简称"公司"）接到持股 5%以上股东 广州云美产业投资合伙企业（有限合伙）通知，该股东于 2025 年 3 月 3 日至 3 月 4 日期间通过集中竞价交易方式合计减持公司无限售条件流通股 434,519 股，占公司 总股本的 0.51%。 本次权益变动前，广州云美产业投资合伙企业（有限合伙）持有公司 7,142,857 股，占公司总股本的比例为 8.33%；本次权益变动后，广州云美产业投资合伙企业 （有限合伙）持有公司 6,708,338 股，占公司总股本的比例由 8.33%减少至 7.82%， 权益变动触及 1%整数倍的情形。现将具体情况公告如下： 三、所涉后续事项 （一）本次权益变动不会导致公司控股股东及实际控制人发生变化，不会对公 司生产经营产生不利影响； | ...

Investment Rating - The report maintains a "Recommended" investment rating for the company Bawei Co., Ltd. (837023.BJ) [1] Core Views - The company's revenue continues to grow rapidly due to the effectiveness of its major customer and single product strategy, achieving a revenue of 695 million yuan in 2024, a year-on-year increase of 48.24% [3][4] - The net profit attributable to shareholders for 2024 is projected to be 45.73 million yuan, reflecting a year-on-year growth of 11.11% [4] - The company is focusing on optimizing its customer and product structure to improve its gross margin, which has been affected by changes in its client base [3] - The cosmetics contract manufacturing industry is expanding, and the company is well-positioned to increase its market share by leveraging its strong R&D capabilities and supply chain management [3] Financial Performance Summary - **Revenue Forecast**: - 2024: 695 million yuan (up 48.24%) - 2025: 861 million yuan (up 23.97%) - 2026: 988 million yuan (up 14.67%) [4][7] - **Net Profit Forecast**: - 2024: 45.73 million yuan (up 11.11%) - 2025: 60.25 million yuan (up 31.74%) - 2026: 74.55 million yuan (up 23.74%) [4][7] - **Earnings Per Share (EPS)**: - 2024: 0.53 yuan - 2025: 0.70 yuan - 2026: 0.87 yuan [4][7] - **Price-to-Earnings (P/E) Ratio**: - 2024: 32.59 - 2025: 24.74 - 2026: 19.99 [4][7] Industry Outlook - The cosmetics industry is experiencing rapid growth driven by increasing consumer spending power, and the contract manufacturing segment is expected to see higher concentration as companies focus on maximizing profits [3] - The company aims to expand its production capacity and enhance its competitive edge through a comprehensive quality control system and a robust supply chain [3]

一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2025 年 2 月 28 日至 2025 年 3 月 3 日）以内收盘 价涨幅偏离值累计达到 41.27%，根据《北京证券交易所交易规则（试行）》的有关规定，属 于股票交易异常波动情形。 证券代码：837023 证券简称:芭薇股份 公告编号：2025-009 广东芭薇生物科技股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 三、是否存在应披露而未披露的重大信息的声明 本公司董事会确认，本公司没有任何根据《北京证券交易所股票上市规则（试行）》等 有关规定应披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等，董事会也未 获悉本公司有根据《北京证券交易所股票上市规则（试行）》等有关规定应披露而未披露的、 对本公司股票交易价格产生较大影响的信息。 四、公司及控股股东、实际控制人、董监高在异常波动期间交易公司股票的情况 公司及控股股东、实际控制人、董监高在异常波动期间不存在交易公司股票的情况。 二、公司关注 ...